Executive Narrative
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
-
Total revenue growth of 44% was primarily driven by Recorlev's commercial team successfully transitioning from a build phase to a yield phase.
-
Recorlev's 93% year-over-year revenue increase resulted from record referrals and new patient starts following a strategic sales force expansion in January.
-
Gvoke achieved a better-than-expected back-to-school prescription lift, signaling a return to a sustainable growth trajectory despite technical revenue adjustments.
-
KEVEYIS performance was bolstered by a new patent extending protection to 2043, allowing management to intensify patient identification efforts in the ultra-rare PPP community.
-
Market expansion for Recorlev is being fueled by updated clinical guidelines from the ADA and EASD that recommend screening for hypercortisolism in difficult-to-control diabetes.
Forward-Looking Commentary
-
Management raised the 2030 revenue outlook to over $1 billion, citing a faster-than-anticipated growth curve for Recorlev and steady contributions from the broader portfolio.
-
Recorlev is now expected to reach its $1 billion annual net revenue milestone three to four years sooner than the company's previous projections.
-
The pivotal Phase III Cornerstone study for XP-8121 remains on track for year-end initiation, with potential regulatory approval and launch targeted for 2030.
-
Future capital allocation will prioritize internal commercial assets and pipeline development, with a secondary focus on M&A that leverages the existing endocrine footprint.
Notable Items & Risk Factors
-
Gvoke net revenue was negatively impacted by a $4 million one-time gross-to-net adjustment specifically related to the Medicaid channel.
-
Full-year R&D expense guidance was reduced to a $15 million increase over 2025 due to the specific timing of expenditures for the XP-8121 program.
-
SG&A guidance was increased to a $60 million year-over-year rise to account for higher personnel costs and deliberate investments in near-term growth opportunities.
Q&A Highlights
Sustainability of Recorlev growth and 2027 payer dynamics
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
-
Momentum is driven by both new and repeat prescribers across the board, which management expects will mitigate typical early-year payer challenges.
Strategic significance of new IP for KEVEYIS and XP-8121
-
The KEVEYIS patent provides the long-term durability needed to invest in finding ultra-rare patients, while XP-8121 patents include strong composition of matter protection.
Impact of updated ADA/EASD screening guidelines on market volume
-
The guidelines encourage screening beyond the endocrinology community into primary care for patients with resistant cardiometabolic conditions, expanding the addressable market.
Evidence generation for Recorlev in treatment-resistant diabetes
-
Management is investing in real-world evidence and clinical data to position Recorlev as a leader in managing cortisol-driven comorbidities over the next several years.
